- Home
- BGH vs SGHT Comparison
BGH vs SGHT Comparison
Compare BGH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGH
- SGHT
- Stock Information
- Founded
- BGH 2012
- SGHT 2011
- Country
- BGH United States
- SGHT United States
- Employees
- BGH N/A
- SGHT N/A
- Industry
- BGH Investment Managers
- SGHT Medical Specialities
- Sector
- BGH Finance
- SGHT Health Care
- Exchange
- BGH Nasdaq
- SGHT Nasdaq
- Market Cap
- BGH 308.6M
- SGHT 304.4M
- IPO Year
- BGH N/A
- SGHT 2021
- Fundamental
- Price
- BGH $16.10
- SGHT $3.95
- Analyst Decision
- BGH
- SGHT Buy
- Analyst Count
- BGH 0
- SGHT 7
- Target Price
- BGH N/A
- SGHT $6.58
- AVG Volume (30 Days)
- BGH 61.5K
- SGHT 227.7K
- Earning Date
- BGH 01-01-0001
- SGHT 11-07-2024
- Dividend Yield
- BGH 10.06%
- SGHT N/A
- EPS Growth
- BGH N/A
- SGHT N/A
- EPS
- BGH N/A
- SGHT N/A
- Revenue
- BGH N/A
- SGHT $79,543,000.00
- Revenue This Year
- BGH N/A
- SGHT $2.18
- Revenue Next Year
- BGH N/A
- SGHT $8.14
- P/E Ratio
- BGH N/A
- SGHT N/A
- Revenue Growth
- BGH N/A
- SGHT N/A
- 52 Week Low
- BGH $11.92
- SGHT $2.71
- 52 Week High
- BGH $14.50
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- BGH 62.13
- SGHT 42.09
- Support Level
- BGH $16.03
- SGHT $3.65
- Resistance Level
- BGH $16.34
- SGHT $4.12
- Average True Range (ATR)
- BGH 0.16
- SGHT 0.19
- MACD
- BGH 0.03
- SGHT 0.07
- Stochastic Oscillator
- BGH 77.14
- SGHT 37.50
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.